Literature DB >> 17320050

NMDA-induced interleukin-1beta expression is mediated by nuclear factor-kappa B p65 in the retina.

Yasushi Kitaoka1, Yasunari Munemasa, Toru Nakazawa, Satoki Ueno.   

Abstract

Transcription factors of the nuclear factor-kappa B (NF-kappaB) p65/RelA may be involved in neuronal cell death. We examined the involvement of NF-kappaB p65 in N-methyl-D-aspartate (NMDA)-induced upregulation of interleukin (IL)-1beta, a proinflammatory cytokine, and subsequent neurotoxicity in the rat retina. Immunohistochemistry showed that IL-1beta is localized not only in glial cells, but also in neurons, especially retinal ganglion cells (RGCs) after intravitreal injection of NMDA. Semi-quantitative real-time PCR showed that NMDA induces an increase in IL-1beta mRNA levels. Preinjection of NF-kappaB p65 antisense oligodeoxynucleotide (AS ODN) ameliorated the NMDA-induced increase in IL-1beta mRNA expression. Western blot analysis showed elevated levels of retinal IL-1beta protein 12 h after intravitreal NMDA injection and this elevation was significantly inhibited by NF-kappaB p65 AS ODN. Neurotracer labeling showed that the inhibition of NF-kappaB p65 by AS ODN or siRNA exerted a protective effect against NMDA-induced RGC loss. IL-1beta siRNA also had a protective effect on RGC number in NMDA-treated eyes. Penetration of AS ODN and siRNA to cells in the RGC layer and inner nuclear layer was confirmed after labeling with rhodamine or Cy3. These results suggest that NF-kappaB p65 may participate in the induction of IL-1beta expression in NMDA-induced retinal neuronal cell death and that the inhibition of NF-kappaB p65 and IL-1beta with the use of AS ODN or siRNA may be a viable neuroprotective strategy for RGC survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320050     DOI: 10.1016/j.brainres.2007.01.097

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity.

Authors:  Mohammed M H Al-Gayyar; Mohammed A Abdelsaid; Suraporn Matragoon; Bindu A Pillai; Azza B El-Remessy
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Ketamine and the myenteric plexus in intestinal ischemia/reperfusion injury.

Authors:  Francisco Javier Guzmán-de la Garza; Carlos Rodrigo Cámara-Lemarroy; Raquel Guadalupe Ballesteros-Elizondo; Gabriela Alarcón-Galván; Paula Cordero-Pérez; Nancy Esthela Fernández-Garza
Journal:  Dig Dis Sci       Date:  2009-09-16       Impact factor: 3.199

3.  PPARγ ameliorated LPS induced inflammation of HEK cell line expressing both human Toll-like receptor 4 (TLR4) and MD2.

Authors:  Reyhaneh Darehgazani; Maryam Peymani; Motahare-Sadat Hashemi; Mir Davood Omrani; Abolfazl Movafagh; Kamran Ghaedi; Mohammad Hossein Nasr-Esfahani
Journal:  Cytotechnology       Date:  2015-07-30       Impact factor: 2.058

4.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

5.  Protection of retinal ganglion cells by caspase substrate-binding peptide IQACRG from N-methyl-D-aspartate receptor-mediated excitotoxicity.

Authors:  Masaaki Seki; Walid Soussou; Shin-ichi Manabe; Stuart A Lipton
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-08       Impact factor: 4.799

6.  Glutamate-induced NFkappaB activation in the retina.

Authors:  Wei Fan; Nigel G F Cooper
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-03       Impact factor: 4.799

7.  IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease.

Authors:  M Kidd; B I Gustafsson; I Drozdov; I M Modlin
Journal:  Neurogastroenterol Motil       Date:  2008-10-25       Impact factor: 3.598

8.  VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.

Authors:  Richard H Foxton; Arthur Finkelstein; Sauparnika Vijay; Annegret Dahlmann-Noor; Peng T Khaw; James E Morgan; David T Shima; Yin-Shan Ng
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

9.  Intrathecal siRNA against Toll-like receptor 4 reduces nociception in a rat model of neuropathic pain.

Authors:  Fei-xiang Wu; Jin-jun Bian; Xue-rong Miao; Sheng-dong Huang; Xue-wu Xu; De-jun Gong; Yu-ming Sun; Zhi-jie Lu; Wei-feng Yu
Journal:  Int J Med Sci       Date:  2010-08-02       Impact factor: 3.738

10.  Molecular mechanisms of retinal ganglion cell degeneration in glaucoma and future prospects for cell body and axonal protection.

Authors:  Yasunari Munemasa; Yasushi Kitaoka
Journal:  Front Cell Neurosci       Date:  2013-01-09       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.